Ezetimibe (Zetia) Indications Dosage
Ezetimibe (Zetia) Indications and Dosage
For use as adjunctive therapy to diet and exercise for the reduction of elevated total cholesterol, LDL-cholesterol, and Apo-B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia, homozygous familial sitosterolemia, or homozygous familial hypercholesterolemia:
NOTE: Concurrent use of ezetimibe with fibrates is not recommended until clinical trial data are available.
for monotherapy:
Oral dosage:
Adults, including the elderly: 10 mg PO once daily.
Adolescents and children >= 10 years: 10 mg PO once daily.
Children < 10 years: Not recommended.
for use in combination with a HMG-CoA reductase inhibitor (’statin’):
Oral dosage:
Adults, including the elderly: 10 mg PO once daily. The daily dosage may be given at the same time as the HMG-CoA reductase inhibitor. Monitor for myopathy, drug interactions, and elevated hepatic enzymes as indicated for the specific HMG-CoA reductase inhibitor.
Adolescents and children >= 10 years: 10 mg PO once daily.
Children < 10 years: Not recommended.
Maximum Dosage Limits:
- Adults: 10 mg/day PO.
- Elderly: 10 mg/day PO.
- Adolescents: 10 mg/day PO.
- Children >= 10 years: 10 mg/day PO.
- Children < 10 years: Not recommended.
Patients with hepatic impairment:
No dosage adjustment is needed in patients with mild hepatic impairment. Due to insufficient data, the manufacturer does not recommend ezetimibe for patients with moderate to severe hepatic impairment.
Patients with renal impairment:
No dosage adjustment is needed.
Intermittent hemodialysis:
No dosage adjustment is needed.
[ Last revised: 11/25/2002 11:05:00 AM ]
Related entries
Syndicate
|
